Haematologica
HAEMATOL/2018/203729
Version 4
Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms

Kaitlyn Shank, Andrew Dunbar, Priya Koppikar, Maria Kleppe, Julie Teruya-Feldstein, Isabelle Csete, Neha Bhagwat, Matthew Keller, Outi Kilpivaara, Franziska Michor, Ross L. Levine, and Laura de Vargas Roditi

Contributions: In regards to author contribution, K.S., F.M., R.L.L. and L.D.V.R. conceived the study. K.S. and L.D.V.R. performed all experiments with help from A.D., P.K., N.B., M.K., I.C., and O.K.. L.D.V.R and K.S. performed the in vitro experiments with help from O.K. while K.S. performed the in vivo experiments with help from A.D., P.K. N.B., M.K. and I.C.. The analysis of pathology slides was performed by J.T.. L.D.V.R. developed the mathematical model and performed computational simulations. K.S., F.M., R.L.L. and L.D.V.R wrote the manuscript. All authors provided feedback on the manuscript.